- Short Report
- Open Access
Gene expression in early and progression phases of autosomal dominant polycystic kidney disease
BMC Research Notes volume 1, Article number: 131 (2008)
Little is known about the genes involved in the initial cyst formation and disease progression in autosomal dominant polycystic kidney disease (ADPKD); however, such knowledge is necessary to explore therapeutic avenues for this common inherited kidney disease.
To uncover the genetic determinants and molecular mechanisms of ADPKD, we analyzed 4-point time-series DNA microarrays from Pkd1L 3/L 3mice to generate high resolution gene expression profiles at different stages of disease progression. We found different characteristic gene expression signatures in the kidneys of Pkd1L 3/L 3mice compared to age-matched controls during the initial phase of the disease. By postnatal week 1, the Pkd1L 3/L 3kidney already had a distinctive gene expression pattern different from the corresponding normal controls.
The genes differentially expressed, either induced or repressed, in ADPKD are important in immune defense, cell structure and motility, cellular proliferation, apoptosis and metabolic processes, and include members of three pathways (Wnt, Notch, and BMP) involved in morphogenetic signaling. Further analysis of the gene expression profiles from the early stage of cystogenesis to end stage disease identified a possible gene network involved in the pathogenesis of ADPKD.
ADPKD is one of the most common lethal genetic diseases in the world, with a prevalence of about one in every 400 to 1000 persons and a 50% chance that an ADPKD patient will die of kidney failure [1–3]. Early changes in the disease process are very important, and unraveling more of the initial steps in pathogenesis may afford patients better management possibilities and an improved prognosis. Determining the molecular mechanism of the pathogenesis of ADPKD, including the early period of cyst formation, requires investigation of changes from before the earliest period of disease manifestation in a defined animal model that mimics the human disease [4–6]. One well-used approach to unravel the molecular pathogenesis and pharmacology of metabolic and genetic diseases is the cDNA microarray [7–9]. We have previously developed an animal model of ADPKD by generating Pkd1L 3/L 3mutant mice . Homozygous Pkd1 null mice appear normal when born, but rapidly develop polycystic kidneys and generally do not live longer than 3.5 to 4 weeks. Here we refined the genetic background of our Pkd1L 3/L 3mutant mice so that the disease more closely resembles most human ADPKD individuals in the late onset of symptoms and final progression to end-stage renal disease (ESRD). This refined animal model will facilitate the study of ADPKD progression and the evaluation of possible treatments. In this paper we present the gene expression profile of Pkd1L 3/L 3mice and their normal littermates at different time points, as determined by cDNA microarray. The materials and methods used in this study were described detail in the additional file 1.
Characterization of Pkd1L 3/L 3Mice on a Congenic C57BL/6 Background
During the course of refinement of the genetic background of the ADPKD model mice to a congenic C57BL/6 genetic background, an earlier onset of polycystic kidney phenotype (see Additional file 2) was seen than with the previous mice on the SV129/C57BL6 background. Histological examination revealed that the translucent enlarged kidneys were due to the formation of numerous large cysts in homozygous mutant mice. Smaller cysts formed early in PNW 1, and became larger at PNW 2. The cysts were disseminated and distributed cross the cortex and medulla. At PNW 3.5, the cyst occupied the entire kidney and normal kidney architecture was hardly seen (see Additional file 2C). All Pkd1L 3/L 3mice were born normally, but most of them did not survive past four weeks (see Additional file 3A) in the congenic C57BL/6 background. In gross appearance, there was no difference between Pkd1L 3/L 3mice and their age-matched control littermates at PNW 1, but Pkd1L 3/L 3mice were shorter of stature with a slightly wider abdomen by PNW 2, and more obviously so by PNW 3 (see Additional file 2A). On necropsy, these homozygous mutant mice had much enlarged and translucent kidneys compared to their heterozygous or wild-type littermates (see Additional file 2B). The gross kidney alterations were first seen at PNW 2 and became more severe at later time points. Although the body weight was only moderately reduced in homozygous mutants (see Additional file 3B), there was a large increase in kidney weight/body weight ratio (kw/bw) (see Additional file 3C) and kidney volume (see Additional file 3D) in homozygous mutant mice. Similar changes in kidney volume were seen in Pkd1L 3/L 3mice compared to the control littermates. Renal function was also severely impaired in homozygous mutant mice as evidenced in the progressive rise in BUN (see Additional file 3E).
Overview of Temporal Expression Profile of Pkd1L 3/L 3Kidney
To study the detailed gene expression profile of ADPKD, we generated and compared gene expression profiles of Pkd1L 3/L 3mice and their aged-matched wild-type littermates at different stages, i.e. PNW 1, 2, 3 and 3.5.
There were significant differences in expression profile seen at all timepoints examined (Figure 1A). 4,231 genes were found to be differentially expressed in the Pkd1L 3/L 3kidney at one or more timepoint (Figure 1B and see Additional file 4), and these genes were assigned to one of 16 functional categories (Figure 1C) based on a previous classification. The number of genes in each functional class that differed at each time point of the disease was then determined (see Additional file 5) and the top 10 genes in each group according to their gene expression ratio at PNW 3.5 were listed (see Additional file 6).
Validation of Genes Involved in the Wnt, Notch, and BMP Signaling Pathway
In addition, several genes differentially expressed in this model are components of three morphogenetic signaling pathways. Quantitative real time PCR was performed to validate gene expression changes identified by microarray analysis during disease progression (see Additional file 7 for details of primers and conditions). Genes involved in the Wnt, Notch and BMP signaling pathway were examined, and most gene expression patterns were consistent with the microarray results (Figure 2A).
Transcriptome Alteration in Pkd1L 3/L 3Kidney in the Early Phase of ADPKD
An original goal of this study was to identify gene expression alterations in Pkd1L 3/L 3kidney during the initial and progressive phases, which may represent specific landmarks in a molecular signature of ADPKD. A total of 50 genes met these criteria by PNW 1 (see Additional file 8): 16 upregulated genes and 34 downregulated genes. The genes affected were virtually all implicated in adaptive and/or pathogenic mechanisms that might be linked to cystogenesis or disease progression (see Additional file 8). To further confirm the differential gene expression at PNW1 observed with the PKD custom microarray and suggested by IPA as being important, we validated the differential expression of the Klk gene family using quantitative real-time PCR analysis normalized against the housekeeping gene Gapdh. The genes selected were Klk3, Klk1b5, Klk1b8, Klk1b26, Klk1 and Klk1b9. The expression pattern of all selected genes was consistent with the microarray results (Figure 2B). In general, PCR-based estimates of expression change were larger than those observed in the microarray study. These genes may prove useful as potential therapeutic target candidates.
Pathway Analysis of Differentially Expressed Genes in Pkd1L 3/L 3Mice at Initial and Progressive Phase
To gain insight into the potential functional consequences of differentially expressed genes in Pkd1L 3/L 3mice, the differentially expressed genes were analyzed by the program IPA (Table 1). IPA identified 4 significant networks among the early genes altered in the Pkd1L 3/L 3mice at PNW 1, associated with cardiovascular system development and function, gene expression, and cell morphology (Table 1). We also analyzed PNW 2, 3 and 3.5 data with IPA (see Additional file 9), and we found other network might be involved in the pathogenesis of ADPKD during disease progression, such as tissue morphology, development, and cellular movement.
Correlation Analysis Identifies Genes Progressively Induced or Repressed with Disease
In order to find genes related to disease progression, the Pearsons' correlation coefficient of affected genes of Pkd1L 3/L 3mice at PNW 1, 2, 3 and 3.5 was calculated. A small number of genes whose expression was constant in control mice but whose expression either continuously increased or decreased in Pkd1L 3/L 3mice was identified, and the 5 annotated genes most well correlated to disease progression (with P values lower than 0.05) are shown in Table 2 and Figure 3A–E. RT-PCR was performed to validate these five genes. The expression of these genes increased progressively, consistent with the microarray results (Figure 3F–J).
IHC Staining of Transforming Growth Factor Receptor (Tgfβr) 1 and 2 Expression
We also performed immunostaining to investigate TGF-beta receptor expression in kidney at corresponding time points. In PNW 3.5 wild-type mice, there was only faint staining for TGFβ Receptor 1, mainly in renal tubules. In Pkd1L 3/L 3kidney, TGFβ Receptor 1 was strongly expressed in cyst epithelium and interstitium (Figure 4A). The over-expression pattern was also seen with TGFβ Receptor 2. Significantly increased TGFβ Receptor 2 immunostaining was observed in Pkd1L 3/L 3kidney in cyst epithelium, interstitium and distorted glomeruli, in contrast to the weak staining in wild-type littermates (Figure 4B).
Confirmation of PKD Custom Microarray Findings Through Quantitative Real-Time PCR Analyses
To further confirm the differential gene expression at each time point observed with the PKD custom microarray, we validated their differential expression patterns using real time PCR analysis. We randomly selected six up-regulated genes, Zfp711, Lox, Npal1, Spata6, Ptrf and Tgfβr (Figure 5A–F), and four down-regulated genes, F13b, Vstm2, Slc2a2 and Tnfaip8 (Figure 5G–J), and verified their expression level by quantitative real time PCR, normalized against the housekeeping gene Gapdh. The expression pattern of all selected genes was similar to and consistent with the microarray results (Figure 5A–J). In general, PCR-based estimates of expression change were larger than those observed in the microarray study. These genes may prove useful as potential therapeutic target candidates.
Comprehensive gene expression profiles from early to end stage ADPKD were generated from Pkd1L 3/L 3mice, an improved disease model. Several distinct early expression signatures of differentially expressed genes with potential roles in cystogenesis were identified. These genes are involved in several pathways including cell proliferation, apoptosis, transport, and immune defenses. A variety of biochemical pathways are clearly involved in the pathogenesis of ADPKD, both in initial cystogenesis and throughout disease progression, with extensive crosstalk between different pathways. Further investigation of these genes and their associated networks may provide insight into the possible pathogenic mechanisms of ADPKD development, and identify potential diagnostic and prognostic markers and novel therapeutic targets.
Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. The New England journal of medicine. 2008, 359: 1477-1485. 10.1056/NEJMcp0804458.
Torra R: [New therapeutic prospects in autosomal dominant polycystic kidney disease]. Nefrologia. 2008, 28: 257-262.
Gabow PA: Autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993, 22: 511-512.
Di Camillo B, Toffolo G, Nair SK, Greenlund LJ, Cobelli C: Significance analysis of microarray transcript levels in time series experiments. BMC Bioinformatics. 2007, 8 (Suppl 1): S10-10.1186/1471-2105-8-S1-S10.
Storey JD, Xiao W, Leek JT, Tompkins RG, Davis RW: Significance analysis of time course microarray experiments. Proc Natl Acad Sci USA. 2005, 102: 12837-12842. 10.1073/pnas.0504609102.
Vora N, Perrone R, Bianchi DW: Reproductive issues for adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2008, 51: 307-318. 10.1053/j.ajkd.2007.09.010.
Young RA: Biomedical discovery with DNA arrays. Cell. 2000, 102: 9-15. 10.1016/S0092-8674(00)00005-2.
Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet. 2007, 369: 1287-1301. 10.1016/S0140-6736(07)60601-1.
Rathaus M: [New therapies for ADPKD]. G Ital Nefrol. 2007, 24: 526-534.
Jiang ST, Chiou YY, Wang E, Lin HK, Lin YT, Chi YC, Wang CK, Tang MJ, Li H: Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. Am J Pathol. 2006, 168: 205-220. 10.2353/ajpath.2006.050342.
We thank Shu-Yun Tung at the Microarray Core Facility of Institute of Molecular Biology, Academia Sinica for her excellent technical support. We thank Wei-Neng Hung, Kuo-Jen Yen and Hsing-Chun Lin for data processing. This work was supported in part by research grants from the Chen-Han Foundation for Education, Academia Sinica (94M003) and the National Science Council (NSC95-2314-B-303-003).
The authors declare that they have no competing interests.
WCC and HL were involved in designing the study. WCC and YST were involved in the animal breeding, tissue collection, RNA purification, microarray analysis, interpretation, and qPCR validation. WCC was involved in the statistical analysis and involved in data interpretation and writing of the manuscript.
Electronic supplementary material
Additional file 1: Materials and methods. The animal experiment, microarray, data analysis and Real-Time PCR were described detail in this file. (DOC 28 KB)
Additional file 2: Pkd1L3/L3 mutant mice. (A) Gross appearance of Pkd1L3/L3 mutant mice and their normal littermates at postnatal weeks (PNW) 1, 2, 3, and 3.5. Note the progressive abdominal enlargement in Pkd1L3/L3 mutant mice. (B) Kidney morphology of Pkd1L3/L3 mutant mice and normal littermates at PNW 1, 2, 3, and 3.5. The enlarged pale and semi-translucent kidney in Pkd1L3/L3 mutant mice was first seen at PNW 2 and became more evident at later time points. (C) H&E-stained kidney sections at PNW 1, 2, 3, and 3.5. Numerous cysts formed and progressively enlarged in kidney parenchyma in both cortex and medulla. (Scale bar = 2000 μm) All images (A-C) are representative of findings in at least three mice per genotype in two independent experiments. (PPT 2 MB)
Additional file 3: Pkd1L3/L3 mutant mice. Most mutant mice died before 28 days of age. Data from both males and females has been pooled. (A) Survival curves of wild-type (filled circle; n = 15), Pkd1L3/+ (open circle; n = 15), and Pkd1L3/L3 (filled triangle; n = 15) mice. Most mutant mice died before 28 days of age. Data from both males and females has been pooled. Body weight (B), ratio of kidney weight to body weight (%BW; C) and kidney volume (D) of wild-type, Pkd1L3/+, and Pkd1L3/L3 mutant mice were recorded at PNW 1, 2, 3, and 3.5. (E) Deterioration in renal function in Pkd1L3/L3 mutant mice. Mice were sacrificed and sera collected at PNW 1, 2, 3, and 3.5. BUN was determined from plasma concentration; n = 6 at each genotype and age; *, P < 0.05.; **, P < 0.01 compared with wild-type or heterozygous mice, by Student's t-test). (PPT 452 KB)
Additional file 4: Pkd1L3/L3 mice at one or more time points. A table showing all transcripts identified as changing significantly between wild-type and Pkd1L3/L3 mice (Raw: intensity of Pkd1L3/L3 mice; Control: intensity of wild-type; t-test, P < 0.05; relative increase > 1.5 or < 1/1.5), and ranked by the ratio at PNW3.5. We also listed the functional group and clustering number in this table including relative change at each time point, accession number, gene symbol and the number of functional group and cluster group. (XLS 2 MB)
Additional file 5: Pkd1L3/L3 mice and age-matched control littermates. Numbers of genes differentially expressed between Pkd1L3/L3 mice and age-matched control littermates at each time point, grouped by functional categories. (PPT 458 KB)
Additional file 6: The 10 genes with the largest changes in expression in wild-type and Pkd1L3/L3 mice in each functional group, including relative change at each timepoint, accession number and gene symbol (Raw: intensity of Pkd1L3/L3 mice; Control: intensity of wild-type). (XLS 104 KB)
Additional file 7: Primers and experimental conditions of Gapdhand validated genes confirmed with real-time RT-PCR. This table contains a complete list and details of amplification conditions for the primers used in the RT-PCR analysis. (DOC 122 KB)
Additional file 8: Pkd1L3/L3 mice and age-matched control littermates at PNW 1of ADPKD. List of genes that were differentially expressed in wild-type and Pkd1L3/L3 mice at PNW 1. (DOC 96 KB)
Additional file 9: List of Ingenuity networks generated by the focus genes that were differentially expressed in wild-type and Pkd1L3/L3 mice at PNW 2, 3 and 3.5. (DOC 75 KB)
About this article
Cite this article
Chen, WC., Tzeng, YS. & Li, H. Gene expression in early and progression phases of autosomal dominant polycystic kidney disease. BMC Res Notes 1, 131 (2008). https://doi.org/10.1186/1756-0500-1-131
- Autosomal Dominant Polycystic Kidney Disease
- Kidney Volume
- Autosomal Dominant Polycystic Kidney Disease Patient
- Homozygous Mutant Mouse
- Morphogenetic Signaling